Bioequivalence study of MTD201 (Q-Octreotide)

Trial Profile

Bioequivalence study of MTD201 (Q-Octreotide)

Planning
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Octreotide (Primary)
  • Indications Acromegaly; Malignant carcinoid syndrome
  • Focus Pharmacokinetics
  • Most Recent Events

    • 02 Sep 2016 According to a Midatech Pharma media release, the company plans to initiate bio-equivalence study in first half of 2017 which, in the case of positive results, could lead to the potential filing for first marketing authorisations by end 2017 or beginning of 2018.
    • 19 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top